« Raw Material Detectives Coming Soon - Case No. 2 | Main | Raw Material Detectives - Case #2 - The Fouled Filters Part 1 »

06/09/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133f08b5035970b

Listed below are links to weblogs that reference Reprise of Commentary on Sweet/Myriad BRCA 1&2 Ruling:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

A reminder from the WSJ Health blog (Aug 31st) as to why this issue may have real importance to women's health far beyond the arguments in the court room.
http://blogs.wsj.com/health/2010/08/31/study-suggests-importance-of-screening-for-brca-gene-mutations/

bigredbruce

The BioJobBlog recently noted that the FDA will crack down on some suppliers of genetic testing services - is this another reaction to the Sweet ruling - effectively is the FDA recognizing public resistance to genetic test monopolies?
http://www.biojobblog.com/2010/06/articles/biobusiness/fda-begins-reining-in-genetic-testing-companies-its-about-time/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+BioJobBlog+%28Bio+Job+Blog%29&utm_content=Google+Reader

bigredbruce

Lest we forget that a Company's financial health and people's jobs are related - I thought I'd throw in this downstream effect at Myriad from the Sweet ruling.
http://www.thepharmaletter.com/file/95689/myriad-pharma-to-focus-on-oncology-portfolio-cutting-staff-to-conserve-financial-resources.html

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada